Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UroGen Pharma (URGN) EPS (Basic): 2015-2024

Historic EPS (Basic) for UroGen Pharma (URGN) over the last 10 years, with Dec 2024 value amounting to -$2.96.

  • UroGen Pharma's EPS (Basic) fell 35.29% to -$0.69 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.46, marking a year-over-year decrease of 18.49%. This contributed to the annual value of -$2.96 for FY2024, which is 16.62% up from last year.
  • Per UroGen Pharma's latest filing, its EPS (Basic) stood at -$2.96 for FY2024, which was up 16.62% from -$3.55 recorded in FY2023.
  • In the past 5 years, UroGen Pharma's EPS (Basic) ranged from a high of -$2.96 in FY2024 and a low of -$5.90 during FY2020.
  • In the last 3 years, UroGen Pharma's EPS (Basic) had a median value of -$3.55 in 2023 and averaged -$3.77.
  • Its EPS (Basic) has fluctuated over the past 5 years, first declined by 15.23% in 2020, then climbed by 26.20% in 2023.
  • Yearly analysis of 5 years shows UroGen Pharma's EPS (Basic) stood at -$5.90 in 2020, then rose by 15.93% to -$4.96 in 2021, then increased by 3.02% to -$4.81 in 2022, then climbed by 26.20% to -$3.55 in 2023, then grew by 16.62% to -$2.96 in 2024.